- Home
- NBBK vs VALN Comparison
NBBK vs VALN Comparison
Compare NBBK & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- VALN
- Stock Information
- Founded
- NBBK 1892
- VALN 2012
- Country
- NBBK United States
- VALN France
- Employees
- NBBK N/A
- VALN N/A
- Industry
- NBBK
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBBK
- VALN Health Care
- Exchange
- NBBK Nasdaq
- VALN Nasdaq
- Market Cap
- NBBK 718.5M
- VALN 820.0M
- IPO Year
- NBBK N/A
- VALN 2021
- Fundamental
- Price
- NBBK $18.44
- VALN $8.94
- Analyst Decision
- NBBK Buy
- VALN Strong Buy
- Analyst Count
- NBBK 1
- VALN 4
- Target Price
- NBBK $22.00
- VALN $15.75
- AVG Volume (30 Days)
- NBBK 243.2K
- VALN 29.8K
- Earning Date
- NBBK 10-22-2025
- VALN 11-20-2025
- Dividend Yield
- NBBK 1.52%
- VALN N/A
- EPS Growth
- NBBK 423.26
- VALN N/A
- EPS
- NBBK 1.54
- VALN N/A
- Revenue
- NBBK $189,481,000.00
- VALN $230,566,060.00
- Revenue This Year
- NBBK N/A
- VALN $6.86
- Revenue Next Year
- NBBK N/A
- VALN $11.85
- P/E Ratio
- NBBK $11.97
- VALN N/A
- Revenue Growth
- NBBK 30.69
- VALN 25.47
- 52 Week Low
- NBBK $15.09
- VALN $3.62
- 52 Week High
- NBBK $21.05
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- NBBK 57.39
- VALN 36.90
- Support Level
- NBBK $17.91
- VALN $8.50
- Resistance Level
- NBBK $18.70
- VALN $9.05
- Average True Range (ATR)
- NBBK 0.51
- VALN 0.23
- MACD
- NBBK 0.08
- VALN -0.05
- Stochastic Oscillator
- NBBK 74.43
- VALN 31.20
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.